JP2003517457A - 冠状動脈疾患の診断のための脂肪酸類似体 - Google Patents
冠状動脈疾患の診断のための脂肪酸類似体Info
- Publication number
- JP2003517457A JP2003517457A JP2000610528A JP2000610528A JP2003517457A JP 2003517457 A JP2003517457 A JP 2003517457A JP 2000610528 A JP2000610528 A JP 2000610528A JP 2000610528 A JP2000610528 A JP 2000610528A JP 2003517457 A JP2003517457 A JP 2003517457A
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- myocardial
- technetium
- acid
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000194 fatty acid Substances 0.000 title abstract description 53
- 150000004665 fatty acids Chemical class 0.000 title abstract description 52
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract description 50
- 229930195729 fatty acid Natural products 0.000 title abstract description 50
- 208000029078 coronary artery disease Diseases 0.000 title description 3
- 238000003745 diagnosis Methods 0.000 title description 2
- 239000012216 imaging agent Substances 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 7
- 229910052751 metal Inorganic materials 0.000 claims description 30
- 239000002184 metal Substances 0.000 claims description 26
- 229910052702 rhenium Inorganic materials 0.000 claims description 8
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 8
- 229910052713 technetium Inorganic materials 0.000 claims description 7
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 7
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052733 gallium Inorganic materials 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 10
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000002285 radioactive effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 12
- 230000002107 myocardial effect Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 7
- -1 alkyl carbon Chemical compound 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 239000013522 chelant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229940056501 technetium 99m Drugs 0.000 description 5
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OEWPQSWDAXMHQG-UHFFFAOYSA-N [Tc+] Chemical compound [Tc+] OEWPQSWDAXMHQG-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000004129 fatty acid metabolism Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VPYQMEOYEWOVKO-UHFFFAOYSA-N 3h-dithiole-3,5-diamine Chemical class NC1SSC(N)=C1 VPYQMEOYEWOVKO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 2
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XVDFXDQCYAQYIK-UHFFFAOYSA-N [Tc+5] Chemical compound [Tc+5] XVDFXDQCYAQYIK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229940006110 gallium-67 Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- YAONEUNUMVOKNQ-UHFFFAOYSA-N 15-(4-iodophenyl)pentadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC1=CC=C(I)C=C1 YAONEUNUMVOKNQ-UHFFFAOYSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- QSHYGLAZPRJAEZ-UHFFFAOYSA-N 4-(chloromethyl)-2-(2-methylphenyl)-1,3-thiazole Chemical compound CC1=CC=CC=C1C1=NC(CCl)=CS1 QSHYGLAZPRJAEZ-UHFFFAOYSA-N 0.000 description 1
- TYYIOZHLPIBQCJ-UHFFFAOYSA-N 4-[1-(4-aminophenyl)-2,2,2-trichloroethyl]aniline Chemical compound C1=CC(N)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(N)C=C1 TYYIOZHLPIBQCJ-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000005288 Annona lutescens Nutrition 0.000 description 1
- 241000886928 Annona reticulata Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- YORNAKOHJQKRLX-UHFFFAOYSA-N diazecane Chemical compound C1CCCCNNCCC1 YORNAKOHJQKRLX-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- DYIZHKNUQPHNJY-UHFFFAOYSA-N oxorhenium Chemical compound [Re]=O DYIZHKNUQPHNJY-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12929899P | 1999-04-14 | 1999-04-14 | |
| US60/129,298 | 1999-04-14 | ||
| PCT/US2000/010096 WO2000061196A2 (en) | 1999-04-14 | 2000-04-14 | Fatty acid analogs for diagnosis of coronary artery disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003517457A true JP2003517457A (ja) | 2003-05-27 |
| JP2003517457A5 JP2003517457A5 (enExample) | 2007-06-07 |
Family
ID=22439338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000610528A Pending JP2003517457A (ja) | 1999-04-14 | 2000-04-14 | 冠状動脈疾患の診断のための脂肪酸類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6437103B1 (enExample) |
| EP (1) | EP1173226B1 (enExample) |
| JP (1) | JP2003517457A (enExample) |
| AT (1) | ATE337020T1 (enExample) |
| AU (1) | AU778834B2 (enExample) |
| CA (1) | CA2366789C (enExample) |
| DE (1) | DE60030270T2 (enExample) |
| ES (1) | ES2269131T3 (enExample) |
| WO (1) | WO2000061196A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2374743T3 (es) * | 1995-12-01 | 2012-02-21 | Molecular Insight Pharmaceuticals, Inc. | Estereoisómeros de análogos de ácidos grasos para imagen de diagnóstico. |
| EP2963017A1 (en) * | 2002-03-11 | 2016-01-06 | Molecular Insight Pharmaceuticals, Inc. | Technetium-dipyridine complexes, and methods of use thereof |
| JP4951798B2 (ja) * | 2002-04-01 | 2012-06-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 側基脂肪酸撮像剤 |
| MXPA05011189A (es) * | 2003-04-17 | 2006-05-25 | Gen Hospital Corp | Metodo para monitorear el flujo sanguineo y la captacion metabolica en el tejido con acido alcanoico radiomarcado. |
| KR100533674B1 (ko) * | 2004-02-25 | 2005-12-06 | 한국원자력연구소 | 수소화붕소 교환수지를 이용한 레늄 착물의 제조방법 |
| ES2380680T3 (es) * | 2005-06-08 | 2012-05-17 | Ge Healthcare Limited | Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4524059A (en) * | 1983-01-28 | 1985-06-18 | The General Hospital Corporation | Fatty acid analogs |
| US4615876A (en) * | 1983-04-25 | 1986-10-07 | Curators Of The University Of Missouri | Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides |
| US4746505A (en) | 1985-04-26 | 1988-05-24 | President And Fellows Of Harvard College | Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands |
| ES2374743T3 (es) * | 1995-12-01 | 2012-02-21 | Molecular Insight Pharmaceuticals, Inc. | Estereoisómeros de análogos de ácidos grasos para imagen de diagnóstico. |
-
2000
- 2000-04-14 AT AT00922209T patent/ATE337020T1/de not_active IP Right Cessation
- 2000-04-14 ES ES00922209T patent/ES2269131T3/es not_active Expired - Lifetime
- 2000-04-14 EP EP00922209A patent/EP1173226B1/en not_active Expired - Lifetime
- 2000-04-14 US US09/549,732 patent/US6437103B1/en not_active Expired - Fee Related
- 2000-04-14 CA CA2366789A patent/CA2366789C/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/US2000/010096 patent/WO2000061196A2/en not_active Ceased
- 2000-04-14 AU AU42433/00A patent/AU778834B2/en not_active Ceased
- 2000-04-14 JP JP2000610528A patent/JP2003517457A/ja active Pending
- 2000-04-14 DE DE60030270T patent/DE60030270T2/de not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| JPN5002006744, ＪＯＮＥＳ Ｇ Ｓ, ＢＩＯＯＲＧＡＮＩＣ ＆ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ ＬＥＴＴＥＲＳ, 19961022, Ｖ６ Ｎ２０, Ｐ２３９９−２４０４, GB * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2366789C (en) | 2010-09-28 |
| US6437103B1 (en) | 2002-08-20 |
| DE60030270D1 (de) | 2006-10-05 |
| DE60030270T2 (de) | 2007-08-30 |
| WO2000061196A2 (en) | 2000-10-19 |
| AU778834B2 (en) | 2004-12-23 |
| ES2269131T3 (es) | 2007-04-01 |
| EP1173226B1 (en) | 2006-08-23 |
| AU4243300A (en) | 2000-11-14 |
| EP1173226A2 (en) | 2002-01-23 |
| ATE337020T1 (de) | 2006-09-15 |
| CA2366789A1 (en) | 2000-10-19 |
| WO2000061196A3 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4925650A (en) | Technetium -99m complex for examining the renal function | |
| Jurisson et al. | Coordination compounds in nuclear medicine | |
| Meegalla et al. | Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents | |
| Arano | Recent advances In99mTc radiopharmaceuticals | |
| Meegalla et al. | Tc-99m-labeled tropanes as dopamine transporter imaging agents | |
| Meltzer et al. | A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain | |
| Skaddan et al. | Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7α-substituted estradiol complexes | |
| Volkert et al. | Technetium-99m chelates as radiopharmaceuticals | |
| Oya et al. | Small and neutral TcvO BAT, bisaminoethanethiol (N2S2) complexes for developing new brain imaging agents | |
| Kung | New technetium 99m-labeled brain perfusion imaging agents | |
| US9789211B2 (en) | Methods and compositions for positron emission tomography myocardial perfusion imaging | |
| Pirmettis et al. | Novel 99mTc Aminobisthiolato/Monothiolato “3+ 1” Mixed Ligand Complexes: Structure− Activity Relationships and Preliminary in Vivo Validation as Brain Blood Flow Imaging Agents | |
| Uehara et al. | Technetium-99m-labeled long chain fatty acid analogues metabolized by β-oxidation in the heart | |
| NZ263794A (en) | Compound suitable for forming tc and re chelates, radiopharmaceutical compositions thereof | |
| Walther et al. | Synthesis and biological evaluation of a new type of 99mTechnetium-labeled fatty acid for myocardial metabolism imaging | |
| Yamamura et al. | Technetium-99m-labeled medium-chain fatty acid analogues metabolized by β-oxidation: radiopharmaceutical for assessing liver function | |
| US5037631A (en) | Technetium-99M complex for examinating the renal function | |
| JP2003517457A (ja) | 冠状動脈疾患の診断のための脂肪酸類似体 | |
| Mahmood et al. | 10. TECHNETIUM RADIOPHARMACEUTICALS | |
| Mirtschink et al. | Modified “4+ 1” mixed ligand technetium-labeled fatty acids for myocardial imaging: evaluation of myocardial uptake and biodistribution | |
| JPH11504002A (ja) | 診断医薬品及び治療医薬品としての使用のためのヒドロキシアルキルホスフィン化合物並びにその製造方法 | |
| Cazzola et al. | Labeling of fatty acid ligands with the strong electrophilic metal fragment [99mTc (N)(PNP)] 2+(PNP= diphosphane ligand) | |
| Jain et al. | 68Ga labeled fatty acids for cardiac metabolic imaging: Influence of different bifunctional chelators | |
| Kothari et al. | Synthesis and characterization of 99mTc-and 188Re-complexes with a diamido-dihydroxymethylenephosphine-based bifunctional chelating agent (N2P2-BFCA) | |
| Eckelman et al. | Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070413 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100525 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100817 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101021 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101028 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110419 |